Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis

计划入组 30 人 · 首次发布于 2013 年 9 月 17 日

Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH

计划入组 148 人 · 首次发布于 2016 年 6 月 30 日

4D-310 in Adults With Fabry Disease and Cardiac Involvement

计划入组 18 人 · 首次发布于 2022 年 11 月 29 日

semaphorin 3A antagonists

4D-C102

4D-125

4D pharma

4D PHARMA PLC

United Kingdom

4D Molecular Therapeutics

United States

Vaccinex's Pepinemab Shows Promise in Alzheimer's Disease Trial

Vaccinex Secures $60 Million to Advance Phase 2b Trial of Alzheimer's Drug Pepinemab

Vaccinex to Present New Biomarker Data Supporting Expanded Phase 2b Trial of Pepinemab in Early Alzheimer's Disease